OpGen, Inc. (Nasdaq:OPGN) is a precision medicine company that utilizes its proprietary molecular diagnostic platform to assist healthcare providers in combating multi-drug-resistant infections and enhance patient outcomes. The company’s Acuitas® molecular diagnostic tests detect genetic markers that determine the presence and drug resistance of bacteria and viruses, enabling physicians to prescribe appropriate antibiotics and improve clinical decision-making. OpGen’s primarily depends on the sales of its molecular diagnostic products and related services.
Comps: Phio Pharmaceuticals Corp. (Nasdaq:PHIO), Benitec Biopharma Inc. (Nasdaq:BNTC)
Given that these biotechnology companies have revenues under USD 10 million and negative earnings, it’s worth noting that OpGen outperforms its peers in a few key areas. Specifically, OpGen generated more revenue than the other companies mentioned. Additionally, its return-on-equity is more favorable compared to Benitec Biopharma. Despite the challenging industry landscape, OpGen seems to be better-positioned for growth.